Inhaled corticosteroids in lung diseases

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 8, 2013, Pages 798-803

  Raissy, Hengameh H ^a   Kelly, H William ^a   Harkins, Michelle ^a   Szefler, Stanley J ^b,c,d  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Asthma control; Asthma guidelines; B adrenergic agonists; Corticosteroids

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE;

ASTHMA; BINDING AFFINITY; CANDIDIASIS; CHRONIC DRUG ADMINISTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; COUGHING; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DYSPHONIA; HOARSENESS; HUMAN; LONG TERM CARE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ASTHMA; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84876820523     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201210-1853PP     Document Type: Review

References (78)

1. Medical Research Council. Controlled trial of the effect of cortisone acetate in status asthmaticus. Lancet 1956;ii:803-806.
2. Walters JAE, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009;CD001288 10.1002/14651858.CD001288. pub3.
3. Clark TJH. Effect of beclomethasone dipropionate delivered by aerosol in patients with asthma. Lancet 1972;1:1361-1364.
4. National Institutes of Health, National Heart, Lung, and Blood Institute. Full report of the expert panel: guidelines for the diagnosis and management of asthma (EPR-3) 2007 [Internet]. National Asthma Education and Prevention Program [accessed September 30, 2012]. Available from: http://www.nhlbi.nih.gov/ guidelines/asthma
5. Kelly HW. Potential adverse effects of inhaled corticosteroids. J Allergy Clin Immunol 2003;112:469-478. (Pubitemid 37108546)
6. Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration 2010;80:89-95.
7. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management and prevention of COPD: 2011 update. Am J Respir Crit Care Med (In press)
8. Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011;163:29-43.
9. Kelly HW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother 2009;43:519-527.
10. Derendorf H, Nave R, Drollman A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28:1042-1050. (Pubitemid 46335529)
11. Rossi GA, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulm Pharmacol Ther 2007;20:23-35. (Pubitemid 44648798)
12. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011;377:1032-1045.
13. Elmallah MK, Khan Y, Hochhaus G, Shuster JJ, Hendeles L. Systemic exposure to fluticasone MDI delivered through antistatic chambers. J Allergy Clin Immunol 2011;128:1113-1115.
14. Guilbert TW, Mauger DT, Allen DB, Zeiger RS, Lemanske RF Jr, Szefler SJ, Strunk RC, Bacharier LB, Covar R, Sorkness CA, et al.; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. J Allergy Clin Immunol 2011;128:956-963.
15. Kelly HW. Inhaled corticosteroid dosing: double for nothing? J Allergy Clin Immunol 2011;128:278-281.
16. Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur Respir J 2004;23:552-558. (Pubitemid 38455996)
17. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 2004;59:16-20. (Pubitemid 38067966)
18. Zhang L, Axelsson I, Chung M, Lau J. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. Pediatrics 2011;127:129-138.
19. Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, Lange C, Lazarus R, Sylvia J, Klanderman B, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 2011;365:1173-1183.
20. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DYM. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008;178:682-687.
21. Forno E, Lescher R, Strunk R, Weiss S, Fuhlbrigge A, Celedón JC; Childhood Asthma Management Program Research Group. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol 2011;127:741-749.
22. Sutherland ER, Goleva E, Jackson LP, Stevens AD, Leung DYM. Vitamin D levels, lung function and steroid response in adult asthma. Am J Respir Crit Care Med 2010;181:699-704.
23. Cohen RT, Raby BA, Van Steen K, Fuhlbrigge AL, Celedón JC, Rosner BA, Strunk RC, Zeiger RS, Weiss ST; Childhood Asthma Management Program Research Group. In utero smoke exposure and impaired response to inhaled corticosteroids in children with asthma. J Allergy Clin Immunol 2010;126:491-497.
24. Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics 2009;123:e519-e525.
25. Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012;5:CD002314.
26. Guevara JP, Ducharme FM, Keren R, Nihtianova S, Zorc J. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2006;2:CD003558.
27. Weiler JM, Anderson SD, Randolph C, Bonini S, Craig TJ, Pearlman DS, Rundell KW, Silvers WS, Storms WW, Bernstein DI, et al. American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter. Ann Allergy Asthma Immunol 2010;105(Suppl)S1-S47.
28. Yang IA, Clark MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;CD002991.
29. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, for the TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789. (Pubitemid 46294610)
30. Chapman KR, Barnes NC, Greening AP, Jones PW, Pedersen S. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax 2010;65:747-752.
31. Raissy HH, Blake K. As needed use of inhaled corticosteroids for management of mild persistent asthma in children. Pediatr Allergy Immunol Pulmonol 2011;24:231-233.
32. Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G, et al.; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007;356:2040-2052. (Pubitemid 46789894)
33. Turpeinen M, Nikander K, Pelkonen AS, Syvänen P, Sorva R, Raitio H, Malmberg P, Juntunen-Backman K, Haahtela T. Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki Intervention Childhood Asthma Study). Arch Dis Child 2008;93:654-659.
34. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:650-657.
35. Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2012;12:CD009611.
36. Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF Jr, Sorkness CA, Bloomberg GR, Morgan WJ, Paul IM, et al. CARE Network. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-tosevere intermittent wheezing. J Allergy Clin Immunol 2008;122:1127-1135.
37. Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr, Strunk RC, Covar R, Szefler SJ, Boehmer S, et al.; CARE Network of the National Heart, Lung, and Blood Institute. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011;365:1990-2001.
38. Ducharme FM, Lemire C, Noya FJ, Davis GM, Alos N, Leblond H, Savdie C, Collet JP, Khomenko L, Rivard G, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009;360:339-353.
39. Kelly HW. Alveolar nitric oxide concentration, small airways inflammation, and targeted asthma therapy: are we there yet? J Allergy Clin Immunol 2010;126:736-737.
40. van den Berge M, Ten Hacken NH, van der Wiel E, Postma DS. Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma. Allergy 2013;68:16-26.
41. van den Berge M, ten Hacken NH, Cohen J, Douma WR, Postma DS. Small airway disease in asthma and COPD: clinical implications. Chest 2011;139:412-423.
42. Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann Med 2012;44:146-156.
43. Zeiger RS, Hay JW, Contreras R, Chen W, Quinn VP, Seal B, Schatz M. Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol 2008;121:885-892.
44. Stanciole AE, Ortegón M, Chisholm D, Lauer JA. Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ 2012;344:e608.
45. Wang L, Hollenbeak CS, Mauger DT, Zeiger RS, Paul IM, Sorkness CA, Lemanske RF Jr, Martinez FD, Strunk RC, Szefler SJ, et al.; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial. J Allergy Clin Immunol 2011;127:161-166.
46. Shih YC, Mauskopf J, Borker R. A cost-effectiveness analysis of firstline controller therapies for persistent asthma. Pharmacoeconomics 2007;25:577-590. (Pubitemid 47048041)
47. Oba Y. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am J Manag Care 2009;15:226-232.
48. Briggs AH, Glick HA, Lozano-Ortega G, Spencer M, Balcerley PM, Jones PW, Vestbo J. Is treatment with ICS and LABA cost-effective for COPD? multinational economic analysis of the TORCH study. Eur Respir J 2010;35:532-539.
49. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010;4:CD005533.
50. Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, et al.; Childhood Asthma Research and Education (CARE) Network of the National Heart, Lung, and Blood Institute. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010;362:975-985.
51. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2011;5:CD003137.
52. Essilfie-Quaye S, Ito K, Ito M, Kharitonov SA, Barnes PJ. Comparison of Symbicort versus Pulmicort on steroid pharmacodynamic markers in asthma patients. Respir Med 2011;105:1784-1789.
53. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 2011;364:2473-2475.
54. 2-adrenergic receptor agonists. Pediatrics 2011;128:e1147-e1154.
55. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and longacting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;9:CD006829.
56. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta (2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;3:CD008532.
57. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, et al.; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/ European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59-99.
58. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Panettieri RA Jr, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012; 129(3, Suppl)S9-S23.
59. Vaessen-Verberne AA, van den Berg NJ, van Nierop JC, Brackel HJ, Gerrits GP, Hop WC, Duiverman EJ; COMBO Study Group. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 2010;182:1221-1227.
60. Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, Kattan M, Pongracic JA, Teach SJ, Bloomberg GR, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008;372:1065-1072.
61. de Jongste JC, Carraro S, Hop WC, CHARISM Study Group, Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009;179:93-97.
62. Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, Cherniack RM, Chinchilli VM, Craig T, Denlinger L, et al., for the Asthma Clinical Research Network of the National Heart, Lung and Blood Institute. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 2012;308:987-997.
63. McNichol DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012; 186:1102-1108.
64. Molimard M, Girodet PO, Pollet C, Fourrier-Reglat A, Davelou A, Haramburu F, Fayon M, Tabarin A. Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation. Drug Saf 2008;31:769-774.
65. Lapi F, Kezouh A, Suissa S, Ernst P. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J (In press)
66. Zöllner EW. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids: part 1. Which test should be used? Pediatr Allergy Immunol 2007;18:401-409. (Pubitemid 47039145)
67. Lehouck A, Boonen S, Decramer M, Janssens W. COPD, bone metabolism, and osteoporosis. Chest 2011;139:648-657.
68. Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC, for the CAMP Research Group. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the Childhood Asthma Management Program (CAMP) study. Pediatrics 2008;122:e53-e61.
69. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia JM, Strunk RC for the CAMP Research Group. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012;367:904-912.
70. Pedersen S. Clinical safety of inhaled corticosteroids for asthma in children: an update of long-term trials. Drug Saf 2006;29:599-612. (Pubitemid 44175030)
71. Raissy HH, Williams P, Jacobs A, Kelly HW for the CAMP Research Group. Risk of cataracts in the Childhood Asthma Management Program Cohort. Allergy Clin Immunol 2010;126:389-392.
72. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yeats JC, Vestbo J. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-647.
73. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;17:162-166. (Pubitemid 47057852)
74. Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med 2008;9:389-396. (Pubitemid 352015642)
75. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention [updated 2011; accessed 2013 Mar 26]. Available from: www.ginasthma.org
76. Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet 2013;52:37-42.
77. Lö tvall J, Bakke PS, Bjermer L, Steinshamn S, Scott-Wilson C, Crim C, Sanford L, Haumann B. Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open. 2012;2:e000370.
78. De Bosscher. Selective glucocorticoid receptor modulators. J Steroid Biochem Mol Biol 2010;120:96-104.